An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy
Purpose The purposes of this study, in children who were assessed 1 week after the administration of myelosuppressive chemotherapy were: to compare the total and subscale scores on a generic measure of health-related quality of life (HRQOL) to normative data from healthy children and describe the re...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2011-03, Vol.19 (3), p.353-361 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 361 |
|---|---|
| container_issue | 3 |
| container_start_page | 353 |
| container_title | Supportive care in cancer |
| container_volume | 19 |
| creator | Baggott, Christina R. Dodd, Marylin Kennedy, Christine Marina, Neyssa Matthay, Katherine K. Cooper, Bruce Miaskowski, Christine |
| description | Purpose
The purposes of this study, in children who were assessed 1 week after the administration of myelosuppressive chemotherapy were: to compare the total and subscale scores on a generic measure of health-related quality of life (HRQOL) to normative data from healthy children and describe the relationships between demographic, clinical, and symptom characteristics of children with cancer and generic and disease-specific dimensions of HRQOL.
Methods
Patients (
n
= 61) were predominantly male (52.5%), minority (63.9%), and 14.7 years of age. Children completed the Memorial Symptom Assessment Scale for 10- to 18-year olds, the PedsQL™ Generic and Cancer Modules, and the Karnofsky Performance Status (KPS) scale 1 week after the start of a chemotherapy cycle.
Results
The mean number of symptoms per patient was 10.6. Compared with the normative sample, children with cancer reported significantly lower scores for the total scale and all of the subscales except emotional and social functioning. No significant differences were found between any demographic characteristics and total or subscale scores on the generic or disease-specific measures of HRQOL. Lower KPS scores were associated with poorer generic and disease-specific HRQOL scores. In addition, a higher number of symptoms was associated with poorer generic and disease-specific HRQOL scores. Finally, higher symptom distress scores were associated with poorer generic and disease-specific HRQOL scores.
Conclusion
Among the demographic, clinical, and symptom characteristics studied, poorer functional status and higher symptom burden were associated with significant decreases in HRQOL in children who received myelosuppressive chemotherapy. |
| doi_str_mv | 10.1007/s00520-010-0824-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2909452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A357967389</galeid><sourcerecordid>A357967389</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-88b9b1788d28ce82a05e3cdabf2afe2dd6ac1e5b9d333cb24f77bc507e8c50253</originalsourceid><addsrcrecordid>eNp1ks2P1CAYxhujccfVP8CLafTgqSsfZaAXk8nGr2QTL3omlL7MsKEwC3RMT_7rUruurtEQeAn8noe85Kmq5xhdYIT4m4QQI6hBuExB2mZ-UG1wS2nDKe0eVhvUtbhpKWNn1ZOUrhHCnDPyuDojCDPO2-2m-r7zNZyUm1S2wdfB1PkAtVE6h5jKXuVaGQM6_zw_gHL50ERwKsNQ30zK2TwvKmcNLFUfrBsi-NoE58I36_f1OIMLaToeI6RkT1AYGEOxi-o4P60eGeUSPLut59XX9---XH5srj5_-HS5u2o0oyw3QvRdj7kQAxEaBFGIAdWD6g1RBsgwbJXGwPpuoJTqnrSG814zxEGUlTB6Xr1dfY9TP8KgweeonDxGO6o4y6CsvH_j7UHuw0mSrvwiI8Xg9a1BDDcTpCxHmzQ4pzyEKUnBWrYVbIsL-fIv8jpM0ZfuFggTTtFi92qF9sqBtN6E8qpeLOWOMt5tORVdoS7-QZUxwGh18GBsOb8nwKtAx5BSBHPXIUZyyYxcMyNLZuSSGTkXzYs_v-ZO8SskBSArkMqV30P83dD_XX8AV37PzA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>854127302</pqid></control><display><type>article</type><title>An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Baggott, Christina R. ; Dodd, Marylin ; Kennedy, Christine ; Marina, Neyssa ; Matthay, Katherine K. ; Cooper, Bruce ; Miaskowski, Christine</creator><creatorcontrib>Baggott, Christina R. ; Dodd, Marylin ; Kennedy, Christine ; Marina, Neyssa ; Matthay, Katherine K. ; Cooper, Bruce ; Miaskowski, Christine</creatorcontrib><description>Purpose
The purposes of this study, in children who were assessed 1 week after the administration of myelosuppressive chemotherapy were: to compare the total and subscale scores on a generic measure of health-related quality of life (HRQOL) to normative data from healthy children and describe the relationships between demographic, clinical, and symptom characteristics of children with cancer and generic and disease-specific dimensions of HRQOL.
Methods
Patients (
n
= 61) were predominantly male (52.5%), minority (63.9%), and 14.7 years of age. Children completed the Memorial Symptom Assessment Scale for 10- to 18-year olds, the PedsQL™ Generic and Cancer Modules, and the Karnofsky Performance Status (KPS) scale 1 week after the start of a chemotherapy cycle.
Results
The mean number of symptoms per patient was 10.6. Compared with the normative sample, children with cancer reported significantly lower scores for the total scale and all of the subscales except emotional and social functioning. No significant differences were found between any demographic characteristics and total or subscale scores on the generic or disease-specific measures of HRQOL. Lower KPS scores were associated with poorer generic and disease-specific HRQOL scores. In addition, a higher number of symptoms was associated with poorer generic and disease-specific HRQOL scores. Finally, higher symptom distress scores were associated with poorer generic and disease-specific HRQOL scores.
Conclusion
Among the demographic, clinical, and symptom characteristics studied, poorer functional status and higher symptom burden were associated with significant decreases in HRQOL in children who received myelosuppressive chemotherapy.</description><identifier>ISSN: 0941-4355</identifier><identifier>ISSN: 1433-7339</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-010-0824-y</identifier><identifier>PMID: 20157746</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adolescent ; Analysis ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cancer ; Chemotherapy ; Child ; Children ; Female ; Health ; Humans ; Karnofsky Performance Status ; Male ; Medicine ; Medicine & Public Health ; Neoplasms - drug therapy ; Neoplasms - physiopathology ; Nursing ; Nursing Research ; Oncology ; Original ; Original Article ; Pain Medicine ; Pediatrics ; Quality of Life ; Rehabilitation Medicine ; Severity of Illness Index ; Social psychology ; Surveys and Questionnaires</subject><ispartof>Supportive care in cancer, 2011-03, Vol.19 (3), p.353-361</ispartof><rights>The Author(s) 2010</rights><rights>COPYRIGHT 2011 Springer</rights><rights>Springer-Verlag 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-88b9b1788d28ce82a05e3cdabf2afe2dd6ac1e5b9d333cb24f77bc507e8c50253</citedby><cites>FETCH-LOGICAL-c535t-88b9b1788d28ce82a05e3cdabf2afe2dd6ac1e5b9d333cb24f77bc507e8c50253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-010-0824-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-010-0824-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20157746$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baggott, Christina R.</creatorcontrib><creatorcontrib>Dodd, Marylin</creatorcontrib><creatorcontrib>Kennedy, Christine</creatorcontrib><creatorcontrib>Marina, Neyssa</creatorcontrib><creatorcontrib>Matthay, Katherine K.</creatorcontrib><creatorcontrib>Cooper, Bruce</creatorcontrib><creatorcontrib>Miaskowski, Christine</creatorcontrib><title>An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
The purposes of this study, in children who were assessed 1 week after the administration of myelosuppressive chemotherapy were: to compare the total and subscale scores on a generic measure of health-related quality of life (HRQOL) to normative data from healthy children and describe the relationships between demographic, clinical, and symptom characteristics of children with cancer and generic and disease-specific dimensions of HRQOL.
Methods
Patients (
n
= 61) were predominantly male (52.5%), minority (63.9%), and 14.7 years of age. Children completed the Memorial Symptom Assessment Scale for 10- to 18-year olds, the PedsQL™ Generic and Cancer Modules, and the Karnofsky Performance Status (KPS) scale 1 week after the start of a chemotherapy cycle.
Results
The mean number of symptoms per patient was 10.6. Compared with the normative sample, children with cancer reported significantly lower scores for the total scale and all of the subscales except emotional and social functioning. No significant differences were found between any demographic characteristics and total or subscale scores on the generic or disease-specific measures of HRQOL. Lower KPS scores were associated with poorer generic and disease-specific HRQOL scores. In addition, a higher number of symptoms was associated with poorer generic and disease-specific HRQOL scores. Finally, higher symptom distress scores were associated with poorer generic and disease-specific HRQOL scores.
Conclusion
Among the demographic, clinical, and symptom characteristics studied, poorer functional status and higher symptom burden were associated with significant decreases in HRQOL in children who received myelosuppressive chemotherapy.</description><subject>Adolescent</subject><subject>Analysis</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Children</subject><subject>Female</subject><subject>Health</subject><subject>Humans</subject><subject>Karnofsky Performance Status</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - physiopathology</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Pediatrics</subject><subject>Quality of Life</subject><subject>Rehabilitation Medicine</subject><subject>Severity of Illness Index</subject><subject>Social psychology</subject><subject>Surveys and Questionnaires</subject><issn>0941-4355</issn><issn>1433-7339</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1ks2P1CAYxhujccfVP8CLafTgqSsfZaAXk8nGr2QTL3omlL7MsKEwC3RMT_7rUruurtEQeAn8noe85Kmq5xhdYIT4m4QQI6hBuExB2mZ-UG1wS2nDKe0eVhvUtbhpKWNn1ZOUrhHCnDPyuDojCDPO2-2m-r7zNZyUm1S2wdfB1PkAtVE6h5jKXuVaGQM6_zw_gHL50ERwKsNQ30zK2TwvKmcNLFUfrBsi-NoE58I36_f1OIMLaToeI6RkT1AYGEOxi-o4P60eGeUSPLut59XX9---XH5srj5_-HS5u2o0oyw3QvRdj7kQAxEaBFGIAdWD6g1RBsgwbJXGwPpuoJTqnrSG814zxEGUlTB6Xr1dfY9TP8KgweeonDxGO6o4y6CsvH_j7UHuw0mSrvwiI8Xg9a1BDDcTpCxHmzQ4pzyEKUnBWrYVbIsL-fIv8jpM0ZfuFggTTtFi92qF9sqBtN6E8qpeLOWOMt5tORVdoS7-QZUxwGh18GBsOb8nwKtAx5BSBHPXIUZyyYxcMyNLZuSSGTkXzYs_v-ZO8SskBSArkMqV30P83dD_XX8AV37PzA</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Baggott, Christina R.</creator><creator>Dodd, Marylin</creator><creator>Kennedy, Christine</creator><creator>Marina, Neyssa</creator><creator>Matthay, Katherine K.</creator><creator>Cooper, Bruce</creator><creator>Miaskowski, Christine</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110301</creationdate><title>An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy</title><author>Baggott, Christina R. ; Dodd, Marylin ; Kennedy, Christine ; Marina, Neyssa ; Matthay, Katherine K. ; Cooper, Bruce ; Miaskowski, Christine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-88b9b1788d28ce82a05e3cdabf2afe2dd6ac1e5b9d333cb24f77bc507e8c50253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Analysis</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Children</topic><topic>Female</topic><topic>Health</topic><topic>Humans</topic><topic>Karnofsky Performance Status</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - physiopathology</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Pediatrics</topic><topic>Quality of Life</topic><topic>Rehabilitation Medicine</topic><topic>Severity of Illness Index</topic><topic>Social psychology</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baggott, Christina R.</creatorcontrib><creatorcontrib>Dodd, Marylin</creatorcontrib><creatorcontrib>Kennedy, Christine</creatorcontrib><creatorcontrib>Marina, Neyssa</creatorcontrib><creatorcontrib>Matthay, Katherine K.</creatorcontrib><creatorcontrib>Cooper, Bruce</creatorcontrib><creatorcontrib>Miaskowski, Christine</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baggott, Christina R.</au><au>Dodd, Marylin</au><au>Kennedy, Christine</au><au>Marina, Neyssa</au><au>Matthay, Katherine K.</au><au>Cooper, Bruce</au><au>Miaskowski, Christine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>19</volume><issue>3</issue><spage>353</spage><epage>361</epage><pages>353-361</pages><issn>0941-4355</issn><issn>1433-7339</issn><eissn>1433-7339</eissn><abstract>Purpose
The purposes of this study, in children who were assessed 1 week after the administration of myelosuppressive chemotherapy were: to compare the total and subscale scores on a generic measure of health-related quality of life (HRQOL) to normative data from healthy children and describe the relationships between demographic, clinical, and symptom characteristics of children with cancer and generic and disease-specific dimensions of HRQOL.
Methods
Patients (
n
= 61) were predominantly male (52.5%), minority (63.9%), and 14.7 years of age. Children completed the Memorial Symptom Assessment Scale for 10- to 18-year olds, the PedsQL™ Generic and Cancer Modules, and the Karnofsky Performance Status (KPS) scale 1 week after the start of a chemotherapy cycle.
Results
The mean number of symptoms per patient was 10.6. Compared with the normative sample, children with cancer reported significantly lower scores for the total scale and all of the subscales except emotional and social functioning. No significant differences were found between any demographic characteristics and total or subscale scores on the generic or disease-specific measures of HRQOL. Lower KPS scores were associated with poorer generic and disease-specific HRQOL scores. In addition, a higher number of symptoms was associated with poorer generic and disease-specific HRQOL scores. Finally, higher symptom distress scores were associated with poorer generic and disease-specific HRQOL scores.
Conclusion
Among the demographic, clinical, and symptom characteristics studied, poorer functional status and higher symptom burden were associated with significant decreases in HRQOL in children who received myelosuppressive chemotherapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>20157746</pmid><doi>10.1007/s00520-010-0824-y</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2011-03, Vol.19 (3), p.353-361 |
| issn | 0941-4355 1433-7339 1433-7339 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2909452 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adolescent Analysis Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Chemotherapy Child Children Female Health Humans Karnofsky Performance Status Male Medicine Medicine & Public Health Neoplasms - drug therapy Neoplasms - physiopathology Nursing Nursing Research Oncology Original Original Article Pain Medicine Pediatrics Quality of Life Rehabilitation Medicine Severity of Illness Index Social psychology Surveys and Questionnaires |
| title | An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T04%3A56%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20evaluation%20of%20the%20factors%20that%20affect%20the%20health-related%20quality%20of%20life%20of%20children%20following%20myelosuppressive%20chemotherapy&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Baggott,%20Christina%20R.&rft.date=2011-03-01&rft.volume=19&rft.issue=3&rft.spage=353&rft.epage=361&rft.pages=353-361&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-010-0824-y&rft_dat=%3Cgale_pubme%3EA357967389%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=854127302&rft_id=info:pmid/20157746&rft_galeid=A357967389&rfr_iscdi=true |